Thank you for taking time to provide your feedback to the editors. Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Guidelines for the use of oral 5-HT 3-receptor antagonists have been developed by several national organizations. [102,103,104,105] The following recommendations are based on a review of currently ...
The results of these three large trials established palonosetron as an active and well-tolerated new 5-HT3 antagonist. In the setting of moderately emetogenic chemotherapy, there is a suggestion ...
receptor agonist and a partial 5-HT3 receptor antagonist.GI motility disorders affect 10–15% of the general population, typically before the age of 45. “There is no silver bullet in this area ...
The company’s lead product is a patient-friendly ODF formulation of a selective serotonin 5-HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Study data show ...
Selective Serotonin Receptor (5-HT3) Antagonists Selective serotonin receptor (5-HT3) antagonists work by blocking serotonin. This is a chemical messenger that stimulates a specific part of the ...
Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors with little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors.